Tumor News and Research

RSS

Combination of MET and erlotinib delays lung cancer progression: Study

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics, Inc. today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing.

11 Oct 2010

Researchers develop new approach to treat inflammatory bowel disease

Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases. Delivering short strands of RNA into cells has become a popular research area because of its potential therapeutic applications, but how to deliver them into targeted cells in a living organism has been an obstacle.

11 Oct 2010

Smoking leads to epigenetic changes associated with cancer development: Research

For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer.The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Scientists identify molecular mechanism of muscle stem cell differentiation

Under normal circumstances, adult stem cells reside in muscle tissue, where they can differentiate into a number of different cell types. After an injury (or even a tough workout), muscles are inflamed as cells and molecules flood the area to control damage and begin repairs. When called upon to replace muscle tissue damaged by injury or genetic disease, some muscle stem cells differentiate, becoming new muscle cells, while others make more stem cells. At Sanford-Burnham Medical Research Institute (Sanford-Burnham), a team of scientists led by Pier Lorenzo Puri, M.D., Ph.D., recently uncovered the molecular messengers that translate inflammatory signals into the genetic changes that tell muscle stem cells to differentiate.

11 Oct 2010

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.

11 Oct 2010

Research may offer new therapy targets for drug-resistant breast tumors

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

11 Oct 2010

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

New approach to provide long lasting relief for headache

Most physicians are treating the symptom of headache using medication. Patients often receive temporary relief from the medication but it does not deal with the cause of the headache. The drug companies are sponsoring research programs to test their drugs in conjunction with most "Headache Facilities."

8 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H., professor of Urologic Surgery, will serve as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation study on prostate cancer.

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Matchmaker function may help cardiologists understand the natural repair process after heart attacks

Heart muscle cells do not normally replicate in adult tissue, but multiply with abandoned during development. This is why the loss of heart muscle after a heart attack is so dire-you can't grow enough new heart muscle to make up for the loss.

8 Oct 2010

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

Caris Target Now molecular tumor profiling increases PFS in cancer patients

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from a multi-center, prospective, pilot study published in the Journal of Clinical Oncology.

7 Oct 2010

Tumor News and Research

Combination of MET and erlotinib delays lung cancer progression: Study

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics reports SGN-75 phase I clinical trial data

Researchers develop new approach to treat inflammatory bowel disease

Smoking leads to epigenetic changes associated with cancer development: Research

Scientists identify molecular mechanism of muscle stem cell differentiation

Infinity announces preliminary results of IPI-926 Phase 1 study in patients with solid tumors

Research may offer new therapy targets for drug-resistant breast tumors

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

New approach to provide long lasting relief for headache

Abiraterone Phase III clinical data to be presented at ESMO meeting

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

Matchmaker function may help cardiologists understand the natural repair process after heart attacks

Researchers develop new technique to detect lung cancer

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Cs-131 brachytherapy seed implant can treat metastasized cancer

Role of TGF-ß in cancer diseases

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

Caris Target Now molecular tumor profiling increases PFS in cancer patients

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News